Last reviewed · How we verify
Fosfomycin Oral Suspension
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme enolpyruvate transferase, preventing peptidoglycan cross-linking.
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme enolpyruvate transferase, preventing peptidoglycan cross-linking. Used for Uncomplicated urinary tract infections (acute cystitis), Bacterial infections susceptible to fosfomycin.
At a glance
| Generic name | Fosfomycin Oral Suspension |
|---|---|
| Also known as | Monuril |
| Sponsor | Public Health Service of Amsterdam |
| Drug class | Cell wall synthesis inhibitor |
| Target | MurA (enolpyruvate transferase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Fosfomycin is a broad-spectrum antibiotic that works by disrupting bacterial cell wall formation. It binds to and inactivates MurA (enolpyruvate transferase), an essential enzyme in the early stages of peptidoglycan synthesis. This mechanism is distinct from beta-lactams and allows activity against many gram-positive and gram-negative bacteria, including some resistant strains.
Approved indications
- Uncomplicated urinary tract infections (acute cystitis)
- Bacterial infections susceptible to fosfomycin
Common side effects
- Diarrhea
- Nausea
- Headache
- Vaginitis
Key clinical trials
- New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea (PHASE3)
- Clinical Efficacy of Fosfomycin Trometamol Per os in the Treatment of Documented Male Urinary Tract Infections With ESBL-producing Enterobacteriaceae With ESBL Producing Enterobacteriaceae and Resistance Associated With Fluoroquinolones and Cotrimoxazole (FOSF'HOM) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |